Skip To Main Content
Jubo Yin on Muck Rack

Jubo Yin

As seen in: Nature, Frontiers
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jubo

Contact Jubo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy and safety of pilocarpine for the treatment of presbyopia: a systematic review and meta‑analysis of randomized controlled trials

|
By Huimei Chen, Kai Wu, Juan Deng, Yunfeng Yu, Xiaoyu Zhou, Jubo Yin, Xiaolei Yao, Qianhong Liu, Fangzhi Fu
| Nature Verified
Abstract Pilocarpine, the first Food and Drug Administration-approved ophthalmic solution for presbyopia treatment, has garnered substantial attention owing to its therapeutic efficacy and safety profile. This meta-analysis systematically evaluated the effectiveness and safety of pilocarpine in managing presbyopia.Relevant literature published before April 1, 2025 can be retrieved from Web of Science, Embase, PubMed, and Cochrane Library.
Open in Who Shared Issue with article?

Case Report: Delirium and complications resulting from the abuse of compound liquorice tablets

|
By Liu Liu, Liyao Huang, Yao Chen, Xuhui Zhou, Xiwen Tian, Jubo Yin, Yanjuan Zeng, Shanghao Yang
| Frontiers
CASE REPORT article Front. Psychiatry, 06 July 2026 Sec. Addictive Disorders Volume 17 - 2026 | https://doi.org/10.3389/fpsyt.2026.1870259 This article is part of the Research TopicUnderstanding Concurrent Disorders in Addiction - Treatment Challenges and OpportunitiesView all 4 articles Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.
Open in Who Shared View Duplicates (2) Issue with article?
See all 2 articles